Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients

  • Trevena Inc TRVN has announced data from 30 patients enrolled in the proof-of-concept study of TRV027 in hospitalized COVID-19 patients. 
  • The results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with COVID-19. 
  • The study was led and funded by Imperial College London, with additional support through the British Heart Foundation Imperial Centre for Research Excellence Award.
  • Related: Trevena's TRV027 To Be Tested In NIH-Funded COVID-19 Trial.
  • The primary endpoint was the mean change from baseline D-dimer levels at three days. 
  • D-dimer is a biomarker used to monitor the risk of abnormal clotting throughout the vascular system, and elevated circulating D-dimer levels can also be used to predict the COVID-19 infection.
  • Among TRV027 treated patients, 70% (7 of 10) experienced a reduction in circulating D-dimer, compared to 27% (3 of 11) of patients on placebo. 
  • TRV027 was associated with a 92% probability of a potentially beneficial treatment effect.
  • Post-hoc analysis indicated that patients receiving TRV027 experienced a 12-day reduction in the average length of hospital stay compared to placebo (11.4 vs. 23.3 days), with a median decrease of 4 days (8 vs. 12).
  • Price Action: TRVN stock is up 6.56% at $1.30 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!